Hudson Bay Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Hudson Bay Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,093	Closed	-$1.1M	–	1042
2021 Q2	$1.1M	Hold	11,093	–	–	0.01%	716
2021 Q1	$1.1M	Hold	11,093	–	–	0.01%	660
2020 Q4	$1.11M	Hold	11,093	–	–	0.01%	442
2020 Q3	$1.1M	Hold	11,093	–	–	0.02%	412
2020 Q2	$1.14M	Buy	11,093 +8,333	+302%	+$815K	0.02%	371
2020 Q1	$264K	Buy	+2,760	New	+$270K	0.01%	394

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hudson Bay Capital Management's JSPR Position: Q3 2021 in Review

Hudson Bay Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 11,093 shares — an estimated $1.1M sold.

Hudson Bay Capital Management first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $1.14M in Q2 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Hudson Bay Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Hudson Bay Capital Management sold 11,093 Jasper Therapeutics shares in Q3 2021, an estimated $1.1M.
Hudson Bay Capital Management first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
Hudson Bay Capital Management's Jasper Therapeutics position peaked at $1.14M in Q2 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Hudson Bay Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.